SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 15:36:29 2024-05-21 EDT | Pre-market 02:00:13 | |||
| 4.69 EUR | +2.18% |
|
4.695 | +0.11% |
| Current month | +1.96% | ||
| 1 month | +12.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 4.69 | +2.18% |
| 24-05-20 | 4.59 | +1.32% |
| 24-05-17 | 4.53 | +0.22% |
| 24-05-16 | 4.52 | +0.67% |
| 24-05-15 | 4.49 | +0.22% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 03:36 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VV39WQ |
| ISIN | DE000VV39WQ5 |
| Date issued | 2022-06-28 |
| Strike | 93.32 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.69 € |
|---|---|
| Lowest since issue | 1.29 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Certificates
- Certificat